Hansa Biopharma AB is a Swedish commercial-stage biopharmaceutical company that develops immunomodulatory treatments for rare immunological conditions. The company specializes in a proprietary enzyme technology platform designed to target and cleave pathogenic immunoglobulin G (IgG) antibodies. Its lead therapy, imlifidase (marketed as Idefirix), is a first-in-class enzyme treatment used primarily to enable kidney transplants in highly sensitized patients by preventing antibody-mediated organ rejection. Beyond organ transplantation, Hansa is evaluating its IgG-cleaving enzymes for potential applications in autoimmune diseases and as a pre-treatment to enable gene therapies. Headquartered in Lund, Sweden, the company operates across Europe and the United States, generating revenue through product sales, research partnerships, and licensing agreements.
